Movement Disorders (revue) - Analysis (France)

Index « Auteurs » - entrée « Cristina Sampaio »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Cornel Tancu < Cristina Sampaio < Cynthia Comella  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 27.
[20-40] [0 - 20][0 - 27]
Ident.Authors (with country if any)Title
000327 (2007) Christopher G. Goetz [États-Unis] ; Stanley Fahn [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Matthew B. Stern [États-Unis] ; Barbara C. Tilley [États-Unis] ; Richard Dodel [Allemagne] ; Bruno Dubois [France] ; Robert Holloway [États-Unis] ; Joseph Jankovic [États-Unis] ; Jaime Kulisevsky [Espagne] ; Anthony E. Lang [Canada] ; Andrew Lees (neurologue) [Royaume-Uni] ; Sue Leurgans [États-Unis] ; Peter A. Lewitt [États-Unis] ; David Nyenhuis [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Anette Schrag [Royaume-Uni] ; Jeanne A. Teresi [États-Unis] ; Jacobus J. Van Hilten [Pays-Bas] ; Nancy Lapelle [États-Unis]Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan
000340 (2007) Bruno Dubois [France] ; David Burn [Royaume-Uni] ; Christopher Goetz [États-Unis] ; Dag Aarsland [Norvège] ; Richard G. Brown [Royaume-Uni] ; Gerald A. Broe [Australie] ; Dennis Dickson [États-Unis] ; Charles Duyckaerts [France] ; Jefferey Cummings [États-Unis] ; Serge Gauthier [Canada] ; Amos Korczyn [Israël] ; Andrew Lees (neurologue) [Royaume-Uni] ; Richard Levy [France] ; Irene Litvan [États-Unis] ; Yoshikuni Mizuno [Japon] ; Ian G. Mckeith [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Eduardo Tolosa [Espagne] ; Murat Emre [Turquie]Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
000342 (2007) Anette Schrag [Royaume-Uni] ; Paolo Barone [Italie] ; Richard G. Brown [Royaume-Uni] ; Albert F. G. Leentjens [Pays-Bas] ; William M. Mcdonald [États-Unis] ; Sergio Starkstein [Australie] ; Daniel Weintraub [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis]Depression rating scales in Parkinson's disease: Critique and recommendations
000357 (2006) Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lled [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne]Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
000404 (2005) Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
000431 (2004) Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Carl Counsell [Portugal] ; Nir Giladi [Israël] ; Robert G. Holloway [États-Unis] ; Charity G. Moore [États-Unis] ; Gregor K. Wenning [Autriche] ; Melvin D. Yahr [États-Unis] ; Lisa Seidl [États-Unis]Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease
000436 (2004) Gregor K. Wenning [Autriche] ; Franc Ois Tison [France] ; Klaus Seppi [Autriche] ; Cristina Sampaio [Portugal] ; Anja Diem [Autriche] ; Farid Yekhlef [France] ; Imad Ghorayeb [France] ; Fabienne Ory [France] ; Monique Galitzky [France] ; Tommaso Scaravilli [Royaume-Uni] ; Maria Bozi [Royaume-Uni] ; Carlo Colosimo [Italie] ; Sid Gilman [États-Unis] ; Clifford W. Shults [États-Unis] ; Niall P. Quinn [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche]Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)

List of associated KwdEn.i

Nombre de
documents
Descripteur
24Nervous system diseases
23Humans
21Parkinson's disease
20Parkinson disease
13Severity of Illness Index
11Questionnaires
10Recommendation
10rating scales
8Female
8Parkinson Disease (diagnosis)
8Parkinson Disease (drug therapy)
8Reproducibility of Results
7Male
7Psychometrics
7clinimetrics
6Middle Aged
6Parkinson Disease (physiopathology)
6Parkinson Disease (psychology)
5Aged
5Dopamine agonist
5Force
5Parkinson Disease (complications)
5Parkinson Disease (epidemiology)
4Antiparkinson Agents (therapeutic use)
4Disability Evaluation
4Evaluation scale
4Reliability
4Treatment Outcome
3Age of Onset
3Double-Blind Method
3Evidence-based medicine
3Human
3Levodopa
3Levodopa (therapeutic use)
3Movement Disorders (diagnosis)
3Multiple system atrophy
3Treatment
3Validity
3dopamine agonists
3evidence‐based medicine
3levodopa
3psychometrics
3reliability
3validity
2Activities of Daily Living
2Adult
2Amantadine
2Amine oxidase (flavin-containing)
2Antiparkinson Agents (adverse effects)
2Benzoxazoles (therapeutic use)
2Cognition Disorders (etiology)
2Deep brain stimulation
2Depression
2Diagnostic and Statistical Manual of Mental Disorders
2Dopamine Agonists (therapeutic use)
2Dose-Response Relationship, Drug
2Dyskinesia
2Evaluation Studies as Topic
2Evidence-Based Medicine
2Health Status
2Malignant melanoma
2Motor system disorder
2Multiple System Atrophy (diagnosis)
2Multiple System Atrophy (physiopathology)
2Myelodysplastic syndrome
2Pardoprunox
2Parkinson Disease (surgery)
2Parkinson Disease (therapy)
2Parkinsonian Disorders (drug therapy)
2Partial agonist
2Pergolide (therapeutic use)
2Piperazines (therapeutic use)
2Prevalence
2Psychometrics (standards)
2PubMed (statistics & numerical data)
2Questionnaires (standards)
2Randomized Controlled Trials as Topic
2Revision
2Risk Factors
2Skin cancer
2Skin disease
2amantadine
2anticholinergics
2deep brain stimulation
2depression
2dyskinesia
2melanoma
2monoamine oxidase inhibitors
2monotherapy
2neurosurgery
2partial dopamine agonist
1Acupuncture
1Acupuncture Therapy
1Advisory Committees (standards)
1Aged, 80 and over
1Amantadine (therapeutic use)
1Anhedonia
1Antiparasitic Agents (therapeutic use)
1Antiparkinson Agents (administration & dosage)
1Antiparkinson Agents (classification)

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i -k "Cristina Sampaio" 
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/Author.i  \
                -Sk "Cristina Sampaio" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Cristina Sampaio
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024